Lemonaid Health Offers STENDRAⓇ ED Medication via Petros Collaboration

Lemonaid Health, a prominent telemedicine provider and subsidiary of 23andMe Holding Co., has announced the availability of STENDRAⓇ (avanafil), a prescription medication for erectile dysfunction (ED), through its telehealth services. STENDRAⓇ is manufactured by Petros Pharmaceuticals and is known for its rapid onset of action, with effectiveness beginning as soon as 15 minutes before sexual activity.

By collaborating directly with Petros Pharmaceuticals, Lemonaid Health can offer STENDRAⓇ at more competitive prices. Given that approximately one in ten men experience ED at some point in their lives, Lemonaid Health’s clinicians are equipped to evaluate and prescribe a range of ED medications tailored to various needs and budgets.

Eland Siddle, Head of Pharmacy at Lemonaid Health, expressed enthusiasm about this partnership, stating that it enhances their ability to provide patients with cost-effective and convenient access to branded medications. The inclusion of STENDRAⓇ expands the options available to patients seeking effective treatments for ED.

Lemonaid Health serves patients nationwide and has already treated over 200,000 patients with ED. Their services include medication delivery from a pharmacy licensed in all 50 states, enabling many men to discreetly and legally obtain treatment for a condition that remains significantly undertreated.

STENDRAⓇ (avanafil) is an oral phosphodiesterase 5 (PDE5) inhibitor designed specifically for treating erectile dysfunction. The medication is not approved for use in women or children. The 100-mg and 200-mg tablets of STENDRAⓇ can be taken approximately 15 minutes before sexual activity and require sexual stimulation to be effective. It can be taken with or without food, but excessive alcohol consumption should be avoided as it can increase the likelihood of side effects.

Clinical trials have shown that a small percentage of participants discontinued STENDRAⓇ due to side effects, with discontinuation rates of 1.4%, 2.0%, and 2.0% for the 50 mg, 100 mg, and 200 mg doses, respectively, compared to 1.7% for those on a placebo. Common side effects reported include headache, flushing, nasal congestion, nasopharyngitis, and back pain.

Certain contraindications exist for STENDRAⓇ. It should not be used by individuals taking organic nitrates, those with known hypersensitivity to any component of the medication, or those using a guanylate cyclase stimulator. Additionally, patients with cardiovascular conditions or for whom sexual activity is inadvisable should not use the medication. Patients should inform their healthcare provider about any history of heart issues, high or low blood pressure, or other relevant health conditions before taking STENDRAⓇ.

Interactions with alpha-blockers, other antihypertensives, and significant amounts of alcohol may lead to hypotension. STENDRAⓇ should also not be used in conjunction with other PDE5 inhibitors or ED therapies, and its safety in patients with bleeding disorders or active peptic ulcers is not established. Patients should be advised that STENDRAⓇ does not protect against sexually transmitted diseases, including HIV.

Patients must seek emergency medical treatment for erections lasting longer than four hours, sudden loss of vision, or sudden hearing loss. For more information on STENDRAⓇ, patients are encouraged to read the full Prescribing Information and Patient Information provided by their healthcare provider.

Lemonaid Health, as part of the 23andMe family, provides comprehensive online telemedicine services across the United States, ensuring that patients have access to necessary medications following a consultation with a licensed healthcare provider.